CD8A and melanoma: In addition to improved response by ipilimumab and nivolumab combination, dual TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains) and PD-1 blockade also can improve antitumor CD8+ T cell responses in advanced melanoma patients (6).